vTv Therapeutics (VTVT) Trading Up 37.3% on Insider Buying Activity

Shares of vTv Therapeutics Inc (NASDAQ:VTVT) were up 37.3% on Friday after an insider bought additional shares in the company. The stock traded as high as $6.12 and last traded at $5.56. Approximately 3,642,300 shares were traded during mid-day trading, an increase of 7,230% from the average daily volume of 49,690 shares. The stock had previously closed at $4.05.

Specifically, major shareholder Ronald O. Perelman acquired 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 26th. The shares were purchased at an average price of $4.03 per share, for a total transaction of $201,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Paul G. Savas acquired 15,000 shares of the company’s stock in a transaction that occurred on Thursday, December 7th. The shares were acquired at an average price of $4.56 per share, for a total transaction of $68,400.00. Following the purchase, the director now owns 81,781 shares of the company’s stock, valued at $372,921.36. The disclosure for this purchase can be found here. 0.80% of the stock is owned by insiders.

A number of analysts recently weighed in on the stock. Zacks Investment Research cut shares of vTv Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 15th. Canaccord Genuity set a $15.00 price target on shares of vTv Therapeutics and gave the company a “buy” rating in a research report on Thursday, December 21st. Stifel Nicolaus reiterated a “buy” rating and issued a $12.00 target price on shares of vTv Therapeutics in a research report on Friday, November 3rd. Finally, Citigroup reiterated an “add” rating on shares of vTv Therapeutics in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $14.10.

The company has a market capitalization of $132.89, a P/E ratio of -3.37 and a beta of 0.64.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ameriprise Financial Inc. boosted its position in shares of vTv Therapeutics by 62.7% during the 2nd quarter. Ameriprise Financial Inc. now owns 264,214 shares of the biotechnology company’s stock valued at $1,313,000 after acquiring an additional 101,850 shares in the last quarter. State Street Corp boosted its position in shares of vTv Therapeutics by 2.1% during the 2nd quarter. State Street Corp now owns 98,016 shares of the biotechnology company’s stock valued at $486,000 after acquiring an additional 1,976 shares in the last quarter. JPMorgan Chase & Co. acquired a new stake in shares of vTv Therapeutics during the 3rd quarter valued at about $481,000. Finally, Renaissance Technologies LLC boosted its position in shares of vTv Therapeutics by 4.8% during the 1st quarter. Renaissance Technologies LLC now owns 63,800 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 2,900 shares in the last quarter. Institutional investors own 10.42% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://sportsperspectives.com/2017/12/29/vtv-therapeutics-vtvt-trading-up-37-3-on-insider-buying-activity.html.

vTv Therapeutics Company Profile

vTv Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer’s disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial.

Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply